Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

Mark Jesus M. Magbanua; Nayelis A. Manon; Denise M. Wolf; Samuel Rivero-Hinojosa; Ziad Ahmed; Rosalyn W. Sayaman; Antony Tin; Derrick Renner; Ekaterina Kalashnikova; Lamorna Brown Swigart; Gillian L. Hirst; Christina Yau; Wen Li; Claudine Isaacs; Rebecca Shatsky; Amy S. Clark; Alexandra S. Zimmer; Amy L. Delson; Angel Rodriguez; Minetta C. Liu; Paula R. Pohlmann; Laura J. Esserman; Hope S. Rugo; Angela DeMichele; Laura van ‘t Veer

doi:10.1038/s41467-025-65432-5

Affiliated Institutions

Related Publications

Repeated observation of breast tumor subtypes in independent gene expression data sets

Thérese Sørlie , Robert Tibshirani , Joel S. Parker +13 more

Characteristic patterns of gene expression measured by DNA microarrays have been used to classify tumors into clinically relevant subgroups. In this study, we have refined the p...

2003 Proceedings of the National Academy o... 5372 citations

Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.

Andrea Ciarmiello , Silvana Del Vecchio , P Silvestro +6 more

PURPOSE Since we have previously shown that the efflux rate of technetium 99m (99mTc) sestamibi, a transport substrate of P-glycoprotein (Pgp), is directly correlated with Pgp l...

1998 Journal of Clinical Oncology 149 citations

Breast cancer

Sibylle Loibl , Philip Poortmans , Monica Morrow +2 more

Breast cancer is still the most common cancer worldwide. But the way breast cancer is viewed has changed drastically since its molecular hallmarks were extensively characterised...

2021 The Lancet 1433 citations

Updated New Zealand cardiovascular disease risk-benefit prediction guide

Rod Jackson

<h3>Abstract</h3> Addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved pathological complete response (pCR) rates in early stage Human epiderma...

2000 BMJ 229 citations

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Patrick M. Forde , Jamie E. Chaft , Kellie N. Smith +32 more

Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burd...

2018 New England Journal of Medicine 2056 citations

Publication Info

Year: 2025
Type: article
Volume: 16
Issue: 1
Pages: 9945-9945
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                
                                    Mark Jesus M. Magbanua, 
                                
                                    Nayelis A. Manon, 
                                
                                    Denise M. Wolf
                                
                                et al.
                            
                            (2025). 
                            Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. 
                            Nature Communications
                            , 16
                            (1)
                            , 9945-9945.
                            https://doi.org/10.1038/s41467-025-65432-5
                        

Identifiers

DOI: 10.1038/s41467-025-65432-5